Low α-N-acetylgalactosaminidase plasma concentration correlates with the presence and severity of the bipolar affective disorder

References

• Arango C, Fraguas D, Parellada M. 2014. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophr Bull. 40(Suppl. 2):138–146.
   PubMedGoogle Scholar
• Bora E. 2015. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia. Eur Neuropsychopharmacol. 25(2):158–168.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. 2013. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 54(1):11–27.
   PubMed Web of Science ®Google Scholar
• Brown KM, Tracy DK. 2013. Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol. 3(3):163–176.
   PubMedGoogle Scholar
• Cantz M, Ulrich-Bott B. 1990. Disorders of glycoprotein degradation. J Inherit Metab Dis. 13(4):523–537.
   PubMed Web of Science ®Google Scholar
• Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, Merella S, Nonis A, Serio CD, Montini E, et al. 2012. Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci USA. 109(37):15018–15023.
   PubMed Web of Science ®Google Scholar
• Clark NE, Metcalf MC, Best D, Fleet GWJ, Garman SC. 2012. Pharmacological chaperones for human α-N-acetylgalactosaminidase. Proc Natl Acad Sci USA. 109(43):17400–17405.
   PubMed Web of Science ®Google Scholar
• Conney AH. 1967. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 19(3):317–366.
   PubMed Web of Science ®Google Scholar
• Desnick RJ, Wang AM. 1990. Schindler disease: an inherited neuroaxonal dystrophy due to alpha-N-acetylgalactosaminidase deficiency. J Inherit Metab Dis. 13(4):549–559.
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Folsom TD. 2009. The neurodevelopmental hypothesis of schizophrenia. Schizophr Bull. 35(3):528–548.
   PubMed Web of Science ®Google Scholar
• Felsky D, Voineskos AN, Lerch JP, Nazeri A, Shaikh SA, Rajji TK, Mulsant BH, Kennedy JL. 2012. Myelin-associated glycoprotein gene and brain morphometry in schizophrenia. Front Psychiatry. 3:40.
   PubMedGoogle Scholar
• Gamblin DP, Scanlan EM, Davis BG. 2009. Glycoprotein synthesis: an update. Chem Rev. 109(1):131–163.
   PubMed Web of Science ®Google Scholar
• Hariri AG, Özer GU, Ceylan ME, Ceylan N, Yazan B, Önal O. 1999. Şizofreni etyolojisinde nörogelişimsel hipotez [Neurodevelopmental hypothesis in the etiology of schizophrenia]. Klinik Psikofarmakol BüLteni. 9(2):99–103. Turkish.
   Google Scholar
• Kanzaki T, Wang AM, Desnick RJ. 1991. Lysosomal α-N-acetylgalactosaminidase deficiency, the enzymatic defect in angiokeratoma corporis diffusum with glycopeptiduria. J Clin Invest. 88(2):707–711.
   PubMed Web of Science ®Google Scholar
• Karadağ F, Oral ET, Yalçın FA, Erten E. 2001. Young mani derecelendirme ölçeğinin türkiye’de geçerlik ve güvenilirliği [VALİDİTY and reliability of the young mania rating scale in Turkey]. Turk Psikiyatri Derg. 13(2):107–114. Turkish.
   Google Scholar
• Kloiber S, Rosenblat JD, Husain MI, Ortiz A, Berk M, Quevedo J, Vieta E, Maes M, Birmaher B, Soares JC, et al. 2020. Neurodevelopmental pathways in bipolar disorder. Neurosci Biobehav Rev. 112:213–226.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. 1999. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 46(6):729–739.
   PubMed Web of Science ®Google Scholar
• Michalski J-C, Klein A. 1999. Glycoprotein lysosomal storage disorders: α- and β-mannosidosis, fucosidosis and α-N-acetylgalactosaminidase deficiency. Biochim Biophys Acta Mol Basis Dis. 1455(2-3):69–84.
   Web of Science ®Google Scholar
• Muneer A. 2017. Mixed states in bipolar disorder: etiology, pathogenesis and treatment. Chonnam Med J. 53(1):1–13.
   PubMedGoogle Scholar
• Murray RM, Lewis SW. 1987. Is schizophrenia a neurodevelopmental disorder? Br Med J (Clin Res Ed). 295(6600):681–682.
   PubMed Web of Science ®Google Scholar
• Murray RM, Sham P, Os JV, Zanelli J, Cannon M, McDonald C. 2004. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res. 71(2–3):405–416.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. 1991. Neurodevelopmental aspects of bipolar affective disorder. Biol Psychiatry. 29(1):1–2.
   PubMed Web of Science ®Google Scholar
• Naumchik BM, Gupta A, Flanagan-Steet H, Steet RA, Cathey SS, Orchard PJ, Lund TC. 2020. The role of hematopoietic cell transplant in the glycoprotein disease. Cells. 9(6):1411.
   PubMed Web of Science ®Google Scholar
• Quarles RH. 2007. Myelin-associated glycoprotein (MAG): past, present and beyond. J Neurochem. 100(6):1431–1448.
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Addington AM, Frangou S, Psych MRC. 2005. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 10(5):434–449.
   PubMed Web of Science ®Google Scholar
• Rowland TA, Marwaha S. 2018. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 8(9):251–269.
   PubMed Web of Science ®Google Scholar
• Sakuraba H, Matsuzawa F, Aikawa S-I, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T. 2004. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet. 49(1):1–8.
   PubMed Web of Science ®Google Scholar
• Sanches M, Keshavan MS, Brambilla P, Soares JC. 2008. Neurodevelopmental basis of bipolar disorder: a critical appraisal. Prog Neuropsychopharmacol Biol Psychiatry. 32(7):1617–1627.
   PubMed Web of Science ®Google Scholar
• Schindler D, Bishop DF, Wolfe DE, Wang AM, Egge H, Lemieux RU, Desnick RJ. 1989. Neuroaxonal dystrophy due to lysosomal α-N-acetylgalactosaminidase deficiency. N Engl J Med. 320(26):1735–1740.
   PubMed Web of Science ®Google Scholar
• Tajima Y, Kawashima I, Tsukimura T, Sugawara K, Kuroda M, Suzuki T, Togawa T, Chiba Y, Jigami Y, Ohno K, et al. 2009. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 85(5):569–580.
   PubMed Web of Science ®Google Scholar
• Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones BJ, Starkey M, Webster MJ, Yolken RH, Bahn DS. 2003. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 362(9386):798–805.
   PubMed Web of Science ®Google Scholar
• Turnley AM, Bartlett PF. 1998. MAG and MOG enhance neurite outgrowth of embryonic mouse spinal cord neurons. Neuroreport. 9(9):1987–1990.
   PubMed Web of Science ®Google Scholar
• Varma R, Hoshino AY, Vercellotti JR. 1980. Serum glycoproteins in schizophrenia. Carbohydr Res. 82(2):343–351.
   PubMed Web of Science ®Google Scholar
• Vourc’h P, Andres C. 2004. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. Brain Res Brain Res Rev. 45(2):115–124.
   PubMedGoogle Scholar
• Wang AM, Schindler D, Desnick R. 1990. Schindler disease: the molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy. J Clin Invest. 86(5):1752–1756.
   PubMed Web of Science ®Google Scholar
• Weinberger DR. 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44(7):660–669.
   PubMed Web of Science ®Google Scholar
• Yılmaz S, Öner P. 2022. Could low α-N-acetylgalactosaminidase plasma concentration cause schizophrenia? World J Biol Psychiatry. 1–8.
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 133:429–435.
   PubMed Web of Science ®Google Scholar
• Yu H, Bi W, Liu C, Zhao Y, Zhang D, Yue W. 2014. A hypothesis-driven pathway analysis reveals myelin-related pathways that contribute to the risk of schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 51:140–145.
   PubMed Web of Science ®Google Scholar